A Phase 1, Multi-center, Parallel, Open-label, Pharmacokinetic, Safety, and Tolerability Study of Venglustat Given as a Single Dose in Adult Participants With Mild, Moderate, and Severe Hepatic Impairment and in Matched Participants With Normal Hepatic Function
Overview
- Phase
- Phase 1
- Intervention
- Venglustat (GZ402671)
- Conditions
- Hepatic Function Abnormal
- Sponsor
- Sanofi
- Enrollment
- 26
- Locations
- 6
- Primary Endpoint
- Area under the plasma concentration versus time curve extrapolated to infinity (AUC)
- Status
- Completed
- Last Updated
- 7 months ago
Overview
Brief Summary
This is a parallel, Phase 1, four arm, open-label, single dose, multicenter study to evaluate the impact of hepatic impairment on venglustat exposure following treatment with venglustat.
The purpose of this study is to assess the effect of mild, moderate, and severe hepatic impairment on PK, safety, and tolerability of venglustat compared with normal hepatic function in male and female participants aged 18 to 79 years.
Study details include:
- The total study duration per participant will be up to 42 days, including up to 21 days for screening and approximately 21 days from institutionalization to the end of study (EOS).
- Institutionalization is mandatory until the activities on D5 have been completed.
- Each participant will receive a single dose of venglustat.
- For hepatically impaired participants there will be a screening visit, a multi-day institutionalization visit, and 7 site visits after D5 discharge, including the end of study (EOS) visit.
- For healthy volunteers there will be a screening visit, a multi-day institutionalization visit and 3 site visits after D5 discharge, including the end of study (EOS) visit.
Detailed Description
The duration of the study for a participant in any arm will be up to 42 days. The treatment and follow up periods will last for a combined total of approximately 20 days, while the screening period will be up to 3 weeks, but may be shorter on an individual basis. Screening period: up to 3 weeks (Days -21 to -2). Open-label treatment period with compulsory institutionalization (Days -1 to 5). Follow up period lasting until approximately day 20 ± 2 days post administration. This will include 7 additional site visits (including the EOS visit) for hepatically impaired groups. The group with normal hepatic function will only need to return D6 and D7 for study visit after institutionalization is completed.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Participant must be 18 to 79 years of age inclusive, at the time of signing the informed consent.
- •Body weight between 50.0 and 115.0 kg, inclusive, if male; between 40.0 and 100 kg, inclusive, if female, and body mass index (BMI) within the range 18 to 40 kg/m2, inclusive, at screening.
- •Contraception (with double contraception methods) for male and female participants; not pregnant or breastfeeding for female participants; no sperm donation for male participants.
- •Female participants must refrain from donating ova/ovum.
- •Capable of giving signed informed consent.
- •Participants with mild, moderate, and severe hepatic impairment
- •Stable chronic liver disease assessed by medical history, physical examination, and laboratory values. Hepatic impairment will be assessed according to the Child-Pugh classification, using CPS (Mild hepatic impairment is defined as a total score ranging from 5 to 6, inclusive (CPS-A); Moderate hepatic impairment is defined as a total score ranging from 7 to 9, inclusive (CPS-B); and severe hepatic impairment is defined as a total score ranging from 10 to 15, inclusive (CPS-C).
- •Laboratory parameters within the acceptable range for participants with hepatic impairment; however, serum creatinine should be strictly at or below the upper laboratory norm and eGFR should be \>= 60 mL/min.
- •Participants with normal hepatic function
- •Certified as healthy by a comprehensive clinical assessment (detailed medical history and complete physical examination).
Exclusion Criteria
- •Participant who had severe course of COVID-19 (i.e., hospitalization, extracorporeal membrane oxygenation, mechanically ventilated) within the past 8 weeks.
- •History of current recreational drugs or alcohol abuse.
- •Smoking more than 15 cigarettes or equivalent per day.
- •Symptomatic postural hypotension, whatever the decrease in blood pressure, or asymptomatic postural hypotension defined as a decrease in SBP ≥30 mmHg within 3 minutes when changing from supine to standing position at screening and Day
- •Blood donation within 2 months before inclusion.
- •Positive result on drug or alcohol screen.
- •Sensitivity to any of the study interventions, or components thereof, or drug or other allergy that, in the opinion of the Investigator, contraindicates participation in the study.
- •Any consumption of citrus fruits (grapefruit, orange, etc) or their juices within 5 days before inclusion).
- •Any participant who cannot comply with the following study restrictions: refraining from drinking alcohol, tea, coffee, chocolate, quinine, or caffeine-containing beverages from 1 day before institutionalization and throughout the study duration; following a stable lifestyle with no intensive physical activity from 1 day prior to institutionalization throughout the study duration until after collection of the final PK sample.
- •Positive result on anti-human immunodeficiency virus (HIV) or COVID-19 test.
Arms & Interventions
Participants with mild hepatic impairment
Venglustat single dose on Day 1
Intervention: Venglustat (GZ402671)
Participants with normal hepatic function
Venglustat single dose on Day 1
Intervention: Venglustat (GZ402671)
Participants with moderate hepatic impairment
Venglustat single dose on Day 1
Intervention: Venglustat (GZ402671)
Participants with severe hepatic impairment
Venglustat single dose on Day 1
Intervention: Venglustat (GZ402671)
Outcomes
Primary Outcomes
Area under the plasma concentration versus time curve extrapolated to infinity (AUC)
Time Frame: Baseline to Day 20
Maximum venglustat plasma concentration observed (Cmax)
Time Frame: Baseline to Day 20
Secondary Outcomes
- Number of participants with adverse event (AE), treatment emergent adverse events (TEAEs), serious adverse events (SAEs) and adverse events of special interest (AESI)(Baseline to Day 20)
- Time to maximum venglustat plasma concentration (tmax)(Baseline to Day 20)